Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance Mutations
Robert L. Hudkins(State Street (United States)), Daniel C. Bensen(State Street (United States)), Isaac Hoffman(Electronic BioSciences (United States)), Kirk Nelson(Arcturus Therapeutics (United States)), Alexandra Balcer(State Street (United States)), Melissa Neal(State Street (United States)), Ronald V. Swanson(Diversitech (United States)), Qing Ye(State Street (United States)), Todd J. Harris(State Street (United States)), Marc Rideout(State Street (United States)), Eric Allen(State Street (United States)), Samhita Iyer(State Street (United States)), Caleb B. Frye(State Street (United States)), Jacqueline H. Starrett(State Street (United States))
Cited by 0
Related Papers
Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery
|ACS Chemical Neuroscience|2011|436
Comparative Genomic Analysis of Archaeal Genotypic Variants in a Single Population and in Two Different Oceanic Provinces
|Applied and Environmental Microbiology|2002|171
Neurotrophic 3,9-Bis[(alkylthio)methyl]- and -Bis(alkoxymethyl)-K-252a Derivatives
|Journal of Medicinal Chemistry|1997|120